1. Home
  2. CHGG vs AVXL Comparison

CHGG vs AVXL Comparison

Compare CHGG & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chegg Inc.

CHGG

Chegg Inc.

N/A

Current Price

$0.58

Market Cap

117.4M

Sector

Real Estate

ML Signal

N/A

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

N/A

Current Price

$1.13

Market Cap

115.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHGG
AVXL
Founded
2005
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
117.4M
115.9M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
CHGG
AVXL
Price
$0.58
$1.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
763.2K
★ 1.1M
Earning Date
11-03-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 88.15
N/A
EPS
★ N/A
N/A
Revenue
★ $376,908,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.52
$1.07
52 Week High
$1.56
$7.25

Technical Indicators

Market Signals
Indicator
CHGG
AVXL
Relative Strength Index (RSI) 31.80 32.47
Support Level $0.53 N/A
Resistance Level $0.68 $1.60
Average True Range (ATR) 0.06 0.09
MACD -0.01 0.03
Stochastic Oscillator 9.36 17.65

Price Performance

Historical Comparison
CHGG
AVXL

About CHGG Chegg Inc.

Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Chegg Skilling; and Academic Services, which derives maximum revenue. Geographically, it derives in United States and International.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: